Showing results (81-90 of 118) with videos related to
Sort By:
Pageof 12
The Journal of Pharmacology and Experimental Therapeutics|August 30, 2017
Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of GlioblastomaJanice K Laramy, Minjee Kim, Shiv K Gupta, et al.Scientific Reports|April 18, 2020
Enhancing Brain Retention of a KIF11 Inhibitor Significantly Improves its Efficacy in a Mouse Model of GlioblastomaGautham Gampa, Rajappa S Kenchappa, Afroz S Mohammad, et al.Journal of Neuroscience Methods|August 14, 2021
Methods for intratumoral microdialysis probe targeting and validation in murine brain tumor modelsKarishma Rajani, Ian Olson, Joshua J Jacobs, et al.Neuro-Oncology|May 15, 2015
Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastomaChani M Becker, Rajneet K Oberoi, Stephan J McFarren, et al.Molecular Cancer Therapeutics|August 15, 2012
Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agentsSagar Agarwal, Rajendar K Mittapalli, David M Zellmer, et al.Fluids and Barriers of the CNS|December 20, 2023
Methodological and analytical considerations for intra-operative microdialysisCecile Riviere-Cazaux, Karishma Rajani, Masum Rahman, et al.Molecular Cancer Therapeutics|March 31, 2021
In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory SignalingSani H Kizilbash, Shiv K Gupta, Karen E Parrish, et al.The Journal of Pharmacology and Experimental Therapeutics|September 16, 2024
Factors Influencing the Central Nervous System (CNS) Distribution of the Ataxia Telangiectasia Mutated and Rad3-Related Inhibitor Elimusertib (BAY1895344): Implications for the Treatment of CNS TumorsSneha Rathi, Ann C Mladek, Ju-Hee Oh, et al.Molecular Cancer Therapeutics|October 7, 2015
Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous SystemKaren E Parrish, Ling Cen, James Murray, et al.Fluids and Barriers of the CNS|March 2, 2022
Brain barriers virtual: an interim solution or future opportunity?Brianna M Holder, Shaina E Tolan, Kaleb K Heinrich, et al.Pageof 12